Recent chatter on X about Serina Therapeutics (SER) has been buzzing with activity, particularly around the company's upcoming presentation at the BTIG Biotech Conference. Many users have pointed out the stock's premarket surge and highlighted technical indicators like moving average crossovers and potential for significant momentum. The discussion also frequently notes the company's small float and strong insider ownership as factors that could drive volatility.
Additionally, there’s a focus on Serina’s pipeline, especially its work in Parkinson’s disease treatments, with some expressing optimism about the strategic additions to the board and backing from substantial financial resources. Posts on X also reflect on recent price jumps, with some describing the stock as primed for further gains if volume continues to build. The conversation remains dynamic as investors weigh both the opportunities and risks tied to this biotech player.
Note: This discussion summary was generated from an AI condensation of post data.
Serina Therapeutics Insider Trading Activity
Serina Therapeutics insiders have traded $SER stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $SER stock by insiders over the last 6 months:
- RANDALL MOREADITH (Chief Scientific Officer) has made 0 purchases and 5 sales selling 32,500 shares for an estimated $179,985.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Serina Therapeutics Hedge Fund Activity
We have seen 7 institutional investors add shares of Serina Therapeutics stock to their portfolio, and 10 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- CITADEL ADVISORS LLC added 13,184 shares (+inf%) to their portfolio in Q1 2025, for an estimated $74,753
- MILLENNIUM MANAGEMENT LLC removed 3,830 shares (-26.3%) from their portfolio in Q1 2025, for an estimated $21,716
- TORONTO DOMINION BANK added 3,554 shares (+inf%) to their portfolio in Q1 2025, for an estimated $20,151
- VANGUARD GROUP INC added 3,260 shares (+5.3%) to their portfolio in Q1 2025, for an estimated $18,484
- UBS GROUP AG removed 3,062 shares (-80.4%) from their portfolio in Q1 2025, for an estimated $17,361
- GEODE CAPITAL MANAGEMENT, LLC added 3,010 shares (+11.5%) to their portfolio in Q1 2025, for an estimated $17,066
- NORTHERN TRUST CORP added 2,225 shares (+15.0%) to their portfolio in Q1 2025, for an estimated $12,615
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Serina Therapeutics Analyst Ratings
Wall Street analysts have issued reports on $SER in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 07/14/2025
- Jones Trading issued a "Buy" rating on 03/11/2025
To track analyst ratings and price targets for Serina Therapeutics, check out Quiver Quantitative's $SER forecast page.
Serina Therapeutics Price Targets
Multiple analysts have issued price targets for $SER recently. We have seen 2 analysts offer price targets for $SER in the last 6 months, with a median target of $13.0.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $15.0 on 07/14/2025
- Justin Walsh from Jones Trading set a target price of $11.0 on 03/11/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
